Saturday, 18 May 2024


HEPHAISTOS secures €10.3 M to reach the clinical stage By

Red Rock Resorts CEO Frank Fertitta III sells $40.3m in stock By

PR: HEPHAISTOS secures €10.3 M to reach the clinical stage

HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing.

  • €4.5M seed round led by Elaia with xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business Angels.
  • €5.8M non-dilutive funding from the EIC accelerator, Bpifrance i-Nov, and France 2030 clinical grant.
  • ONCO-Boost is a first-in-class immunostimulant targeting innate immune response to treat cancers non-responding to current regimens, including immunotherapies.

France, May 16th, 2024. HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, has completed its €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic. Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq.

Florian DENIS, Investment Director at Elaia, stated: Elaia is very proud to join and strengthen the syndication. HEPHAISTOS’ core technology based on immunostimulants has the potential to turn cold tumors into hot tumors in hard-to-treat cancers. Frédéric CAROFF and his team have generated impressive preclinical data that will be scaled up towards additional value-creating milestones.

ELAIA has a proven track record in supporting biotech companies through to the clinic and success, and we are delighted to have them on board said Frederic CAROFF, CEO and co-founder of HEPHAISTOS-Pharma. With xista science ventures, Fondation Fournier-Majoie and Noshaq, our consortium of seed investors brings not only the necessary funds, but also complementary expertise and a network that will structure the company. They will play a crucial role in the success of HEPHAISTOS.

3rd party Ad. Not an offer or recommendation by See disclosure here or
remove ads

HEPHAISTOS’ innovative approach to innate modulation has received significant validation and support from prestigious programs, with a total of €5.8 million awarded to accelerate the development of ONCO-Boost for the treatment of hard-to-treat solid tumors, where there is a high unmet medical need, Bpifrance i-Nov national competition, EIC Accelerator European competition and RHU clinical grant from France 2030, that will include a clinical phase 1/2 in collaboration with…

Click Here to Read the Full Original Article at All News…